The present case illustrates the risk of potentially life-threatening toxic side effects of isoniazid in patients at risk, including end-stage renal disease patients on dialysis and/or those harboring a slow acetylator phenotype conferred by NAT2 polymorphisms. This evidence concerns the gene NAT2 and stage 5 chronic kidney disease.